Newron submits new drug application to FDA for Parkinson's disease treatment

Newron Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for safinamide, which is being developed as an add-on therapy to dopamine agonists or to levodopa in patients with early or mid-to-late-sta…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news